The International Council on Infertility Information Dissemination, Inc

COVID-19 Scholarship Medication Giveaway

Team of scrub nurses tinted blue

Due to the current Covid-19 Pandemic Crisis, INCIID is altering the Scholarship With the rapid spread of COVID-19 in recent weeks, there has been a significant impact on all across the healthcare spectrum - patient, provider, and more.
We have a limited number of IVF ovarian stimulation medications from EMD Serono available through application to the scholarship program.

As a leader in patient advocacy, we remain committed to helping patients who have experienced interruptions in their family building journey in recent weeks due to the COVID-19 pandemic. 
To help support our healthcare professionals and their patients, INCIID has a limited number of medications (for Ovarian Stimulation)

We are giving to give those away to qualified applicants who make an application to the  INCIID the Heart Scholarship Program.
There are no fundraising requirements for this medication donation in 2020.

Join us for a Webinar to answer your questions: May 21, 2020, 2 PM ET 

What we need from you is our one-page application, 2 recent paystubs, a financial form (assets and liabilities), the most recent (either 2018 or 2019 tax return), and a compelling video or story.  
All documents can be faxed to (703) 379-1593. This number forwards all faxes to a HIPAA compliant secure fax. We are not taking any paper applications at present.

General Criteria: No insurance for IVF, Infertility as defined by ASRM, and Financial need.

You must be in (IVF treatment) by December 1, 2020. The medications go through your clinic
You will still have to sign a release. If someone in your family has lost their job, document this from your previous employer.
We ask that you honor the $55 donation to support INCIID but if this is a hardship please send us an email explaining your situation. INCIID works very hard at finding matches for scholarship recipients. Due to COVID-19  All donations, memberships, and corporate donations are currently at zero. 

If you have any questions, please do not hesitate to email us. If there is enough interest, please sign up for the Webinar here

In the Future.

EMD Serono has been very generous in their donations to patients, They continue to prioritize patients currently undergoing treatment, or wishing to do so in the future.

EMD Serono has assistance programs and additional information for those who have had their cycle canceled due to COVID-19 and can be found at, EMD Serono is maintaining its focus on ensuring that their medicines, products, and services continue to reach the patients who rely on them. INCIID encourages patients to reach out to EMD Serono for help.


U.S. Pregnancy Products Market to Touch US $439.2 Mn by 2023; Stretch Mark Minimizers Represented Largest Product Segment in 2014: TMR

ALBANY, New York, May 10, 2016 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Pregnancy Products Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023", the pregnancy products market in the U.S. was valued at US$266.6 mn in 2014 and is projected to expand at a CAGR of 5.7% from 2015 to 2023 to reach US $439.2 mn in 2023.

Pregnancy is a temporary, but the most important phase in a woman's life. A pregnant woman has many limitations with respect to the food and medications she takes. Thus, it is essential to use skincare products that prevent or cure skin-related issues and are safe to be used during pregnancy and the postpartum period. Around 6.1 million pregnancies were reported in the U.S. in 2011. The common skin conditions occurring during pregnancy are separated into three categories: hormone-related changes, pre-existing, and pregnancy specific. Most of these occur especially in the second and third trimester of pregnancy. Several products are available in the U.S. in the form of cream, lotion, balm, gel, etc. for pregnant women and nursing mothers.

Download PDF Brochure

Based on product type, the pregnancy products market in the U.S. has been segmented into stretch mark minimizer, body restructuring gel, toning/firming lotion, itching prevention cream, nipple protection cream, breast cream, stressed leg product, and others. The market for these products has been extensively analyzed based on their utility, effectiveness, sales, and region-wise presence.

Increasing number of pregnant women in the U.S. and rise in distribution channels such as hypermarkets, supermarkets, retail stores, and online stores are likely to fuel the growth of the market in the near future. The pregnancy products market in the U.S. is projected to expand at a CAGR of 5.7% during the forecast period from 2015 to 2023. Additionally, growing awareness about pregnancy products among the female population in the U.S. is likely to drive the market in the U.S. However, factors such as side effects associated with pregnancy products could hamper the growth of the pregnancy products market. The report offers a detailed analysis of this high growth and outlines a possible growth trajectory at the regional level in terms of value for each pregnancy product segment.

Browse Research Report

Stretch mark minimizer was the largest product segment of the market in 2014. Around 6.1 million pregnancies were reported in the U.S. in 2011. Nearly 90% of the pregnant women develop stretch marks during pregnancy. Stretch marks are caused due to tearing of dermis. Moreover, stretch marks are developed due to rapid change in weight, also influenced by the change in hormones during puberty, pregnancy, hormone replacement therapy, etc. These stretch marks can be treated with stretch mark minimizer creams and lotions. Factors such as long-term use of stretch mark minimizers (minimum three to five months), rise in birth rate, and increase in the disposable income are set to drive the stretch mark minimizer segment. However, according to some researchers, only a few products are available in the market that can prevent or reduce pregnancy stretch marks. This is likely to hinder the growth of the stretch mark minimizer segment in the near future.

The others segment consists of moisturizing creams, face creams, body wash, and dark spot treatments. During pregnancy, motion sickness, hormone fluctuations, and stress lead to loss of water and vital nutrients from the body, resulting in flaky, dry, and itchy skin. Moisturizing creams and lotions are used to treat these conditions. The others segment is likely to expand at the highest CAGR during the forecast period due to long-term use of products, high disposable income, rising awareness among the female population, and increasing number of pregnancies. The report has been compiled in order to update the stakeholders with the incumbent market dynamics through a graphical illustration and in-depth analysis of major segments for each region considered in the study scope.

Interact with our Pool of Experienced Analysts for Any Report Related Queries:

Market Players: 

Major players operating in the pregnancy products market in the U.S. include Clarins Group, Expanscience Laboratories, Inc. (Mustela), Mama Mio US Inc. (Mio), Noodle & Boo, Novena Maternity, Nine Naturals, LLC, and E.T. Browne Drug Co., Inc. (Palmers). The key market players are actively involved in constant innovations and developments related to technology and application to cater to the multi-dimensional needs of the end-users in order to maintain their positions in the U.S.

Other Reports by TMR: 

  • Telemedicine Technologies and Services Market:

  • Smart Healthcare Products Market:

  • Healthcare M2M Market:

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Mr. Sudip. S
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453



SOURCE Transparency Market Research

12th Edition of the EMD Serono Specialty Digest™ Now Available

Scott Filosi, Senior Vice President, Market Access & Customer Solutions, EMD Serono

Scott Filosi, Senior Vice President, Market Access & Customer Solutions, EMD Serono

Value of specialty medicines, appropriate clinical use identified as critical managed care challenges

ROCKLAND, Mass., May 9, 2016 /PRNewswire/ -- EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced the release of the 12th edition of the EMD Serono Specialty Digest™.  The Digest, which was featured last week at the Asembia Specialty Pharmacy Summit in Las Vegas, NV,  is an industry resource that provides market data on health plans' management of specialty pharmaceuticals in 2015 and identifies common trends occurring across plans. The Digest is available to those who request a copy at

"EMD Serono has a longstanding commitment to customers and patients to further the understanding of trends in the management of specialty pharmaceuticals and ultimately, improve patient outcomes," said Scott Filosi, Senior Vice President, Market Access & Customer Solutions, EMD Serono. "It is our hope that this year's Digest findings will help spur conversations around ways to ensure continued patient access to optimal care." 

The 12th edition of the EMD Serono Specialty Digest includes data from 58 commercial health plans across the country, representing more than 140 million covered lives. New to the Digest this year is an oncology-specific supplement that includes a deeper analysis into the therapeutic category, which continues to be a major focus for health plans.  The new oncology-specific supplement is scheduled to be available in June.

"The findings in the area of oncology shed light on new trends such as the adoption of clinical pathways as well as concerns around restricting product use and the cost of infusion site visits for payers," said Kevin Host, President, Artemetrx, who oversaw the development of this year's Digest. "Understanding these managed care challenges as they relate to oncology is an important step in better meeting the needs of patients."

Further findings from this year's Digest show that while alignment of pharmacy and medical benefits has improved, it still remains a major issue for some plans. Additionally, plans are more likely to select preferred products and to exclude non-preferred agents as a therapy class matures post-launch. 

The EMD Serono Specialty Digest was first developed in 2004 to provide a comprehensive reference for managed care decision makers regarding the management of specialty products. Over the past twelve years, health plans, Pharmacy Benefit Managers (PBMs), employers, specialty pharmacies, and pharmaceutical companies have relied on the Digest to identify current and future trends in the management of specialty pharmaceuticals.

About EMD Serono, Inc. 
EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.

About Merck KGaA, Darmstadt, Germany
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.8 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Your Contact
Melissa Manganello 1-781-681-2393

Photo -